According to the publication in the Official Journal of 13 January 2026, the conditions for reimbursement of Evrysdi (Risdiplam) in oral solution form have been extended to include presymptomatic children. They now apply to a wider range of patients:
- patients with a clinical diagnosis of SMA type I, II and III,
- presymptomatic patients with 1 to 4 copies of the SMN2 gene.
In addition, the marketing authorisation for the drug was renewed on 8 January.
French Official Journal of 13 January 2026.
